A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape

BACKGROUND: Immune checkpoint inhibitor (ICI) therapy has revolutionized the treatment of many cancers. However, the limited population that benefits from ICI therapy makes it necessary to screen predictive biomarkers for stratifying patients. Currently, many biomarkers, such as tumor mutational bur...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Junyu, Wang, Dongxu, Wang, Anqiang, Chen, Peipei, Lin, Yu, Bian, Jin, Yang, Xu, Zheng, Mingjun, Zhang, Haohai, Zheng, Yongchang, Sang, Xinting, Zhao, Haitao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867854/
https://www.ncbi.nlm.nih.gov/pubmed/35197093
http://dx.doi.org/10.1186/s13073-022-01024-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867854/
https://www.ncbi.nlm.nih.gov/pubmed/35197093
http://dx.doi.org/10.1186/s13073-022-01024-y

Ejemplares similares